Deciphering the epigenetics and metabolomics of Leukemia

Super Enhancers

Defining how oncogenic and tumor suppressor enhancers impact tumorigenesis in hematological and solid tumors


Dissecting the interplay between cancer cell-specific metabolic rewiring and epigenetics in T-cell Acute Lymphoblastic Leukemia (T-ALL)

Experimental Therapeutics

Developing in vivo models of epigenetic and metabolic reprograming to test novel therapeutic strategies.

Meet the team

Daniel Herranz

Daniel Herranz, PharmD, PhD

Principal Investigator

Dr. Herranz is Assistant Professor of Pharmacology at Rutgers University. Over the last 10 years, he has pursued a combined training in metabolism, epigenetics and how both affect human cancer development through the generation and analysis of relevant mouse models. After obtaining his doctoral training in Pharmacy from the Complutense University of Madrid, Dr. Herranz completed a Ph.D. in Molecular Biology and Biochemistry from the Autonomous University of Madrid under the supervision of Dr. Manuel Serrano at the Spanish National Cancer Research Center (CNIO). Here, Dr. Herranz addressed the role of Sirt1 in metabolism, cancer and aging. Specifically, he demonstrated for the first time the protective role of Sirt1 from high-fat diet-induced metabolic damage (Pfluger*, Herranz* et al., PNAS, 2008) as well as from spontaneous aging-associated cancers and high-fat diet promoted liver cancers thereby increasing the healthspan of mice (Herranz et al, Nature Communications, 2010). After completing his Ph.D., Dr. Herranz joined the Ferrando laboratory at Columbia University in April 2011 as a Postdoctoral Fellow. During his postdoctoral studies, Dr. Herranz uncovered N-Me as the long-sought missing link in the regulation of MYC by NOTCH1 in T-cells. As such, N-Me is a T-cell specific Myc oncogenic enhancer controlled by Notch1 that is critically required for normal T-cell development and for NOTCH1-induced T-ALL generation and maintenance (Herranz et al, Nature Medicine, 2014). Moreover, Dr. Herranz’s research unveiled that metabolic reprogramming after loss of the PTEN tumor suppressor gene can drive resistance to NOTCH1 inhibition in vivo and revealed a prominent role of glutaminolysis in NOTCH1-driven T-ALL, opening new therapeutic avenues (Herranz et al, Nature Medicine, 2015). Dr. Herranz's group at the Cancer Institute of New Jersey works on the discovery and characterization of enhancer regions critical for cancer cell survival and proliferation, as well as on the interplay between metabolism and epigenetics as a pathogenic mechanism in cancer using T-ALL as a model. The long-term goal of the Herranz lab is to find new therapeutic targets for the treatment of this disease. Full Publication List

In his free time, you can probably find Dr. Herranz at any of the concerts happening around the New York City area. He is a huge fan of Pearl Jam, Radiohead, Wilco, The National and many others! He is also an avid mid-distance runner (10K to half-marathon distances are his favorites, although he recently completed the NYC marathon) and swimming (he proudly swam from Alcatraz to the San Francisco Bay!). More broadly, he is in love with all that New York City has to offer!


Olga Lancho, PhD

Postdoctoral Fellow

Olga earned her degree in Biochemistry from the Universidad Autónoma de Madrid (UAM). Her undergraduate work was performed at the Centro de Biología Molecular Severo Ochoa under the supervision of María Luisa Toribio on an in vitro model of Tregs generation by Mesecnchymal Stem Cells. She obtained her PhD on Molecular Biology in 2017 in the same lab, studying whether Sfrp1 regulates T-cell development and Notch-dependent T-ALL pathogenesis. Olga will join the Herranz Lab at Rutgers University this next October to start her postdoctoral training. During this period, she will focus on the study of metabolic and epigenetic mechanisms of resistance to therapy in T-ALL using mouse models.


Yongping Wang, PhD

Lab Manager

Yongping holds a Ph.D in Marine Biology, she has more than 10 years of laboratory experience in neuroscience and molecular biology. The techniques She excels to perform include nucleic acid and protein isolation and electrophoresis, classical, real-time and digital PCR, western blot, next-generation sequencing (RNA-Seq and chromatin immunoprecipitation (ChIP)), microarrays, SNP analysis, primary cells and cell line cultures, transient transfections, flow cytometry, triploid-tetraploid technology, fluorescence in situ hybridization (FISH), random priming, nick translation and DNA sequencing.

Contact us

We are currently seeking talented post-doctoral fellows with a strong passion for translational research to join our lab. Please Click here for more information and use the form below to contact Professor Herranz about open positions.